UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 3, 2006
BOSTON SCIENTIFIC CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
Delaware |
|
001-11083 |
|
04-2695240 |
(State or Other Jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer Identification |
|
|
|
|
|
One Boston Scientific Place, Natick, Massachusetts |
|
01760-1537 |
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrants Telephone Number, Including Area Code: (508) 650-8000
Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d2(b) under the Exchange Act (17 CFR 240.14d2(b))
o Pre-commencement communications pursuant to Rule 13e4(c) under the Exchange Act (17 CFR 240.13e4(c))
Item 8.01. Other Events
Language was inadvertently left out of the last sentence in the paragraph entitled Endoscopic Video Imaging on page 10 of Boston Scientifics Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2006. The sentence should read as follows: We expect to conduct first-in-man trials of the Endovations System in the second quarter of 2006 and to launch commercially in the U.S. in 2007.
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BOSTON SCIENTIFIC CORPORATION |
||
|
|
|
|
|
By: |
/s/ Lawrence J. Knopf |
|
|
Name: |
Lawrence J. Knopf |
|
|
Title: |
Vice President and Assistant General Counsel |
Dated: March 3, 2006
2